DiRocco Derek 4

What Happened Derek DiRocco, a director of Acrivon Therapeutics (ACRV), was granted 9,366 restricted stock units (RSUs) on May 18, 2026. The Form 4 reports the acquisition as an award (code A) at $0.00 per share (no cash paid). The RSUs vest in full on May 18, 2027, subject to DiRocco’s continued service through that date. Under the filing, DiRocco disclaims beneficial ownership of these RSUs; they are held for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P. and will be turned over to the Adviser to offset advisory fees.

Key Details

• Transaction date: May 18, 2026 (reported on Form 4 filed May 20, 2026) — filing appears timely (within the usual 2-business-day window).
• Transaction type/code: Award/Grant (A).
• Shares/units granted: 9,366 RSUs; reported price $0.00 (award).
• Vesting: RSUs vest in full on May 18, 2027, subject to continuous service.
• Shares owned after transaction: Not specified in the filing.
• Notable footnotes: F1 explains each RSU converts to one share upon vesting; F2 states DiRocco holds the RSUs for RA Capital funds and must turn any shares over to the Adviser to offset advisory fees, and thus disclaims beneficial ownership.

Context RSUs are contingent grants that convert to common stock only upon vesting; this award does not represent an immediate purchase or sale of stock. Because DiRocco disclaims beneficial ownership and the award is held for RA Capital funds to offset fees, this filing reflects a compensation arrangement rather than a personal investment decision by the director.